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Abstract
Background: To evaluate the accuracy of 11C-acetate Positron Emission Tomography/Magnetic Resonance Imaging
(PET/MRI) in bladder cancer (BC) staging and monitoring response to neoadjuvant chemotherapy (NAC).
Methods: Eighteen patients were prospectively enrolled. Fifteen treatment naive patients underwent 11C-acetate
PET/MRI before transurethral resection of bladder tumor (TUR-BT) for primary tumor evaluation. Five patients with
muscle invasive BC were imaged after NAC and prior to radical cystectomy (RC) with extended pelvic lymph node
dissection (ePLND) for NAC treatment response evaluation. Two patients were part of both cohorts. 11C-acetate
PET/MRI findings were correlated with histopathology. Accuracy for lymph node detection was evaluated on
patient and the ePLND template (10 regions) levels.
Results: The sensitivity, specificity and accuracy of 11C-acetate PET/MRI for the detection of muscle invasive BC was
1.00, 0.69 and 0.73 while the area under the receiver operating characteristic curve (95% confidence interval) was 0.
85 (0.55–1.0), respectively. All five NAC patients underwent chemotherapy as planned and 11C-acetate PET/MRI
correctly staged three patients, overstaged one and understaged one patient compared with RC and ePLND
findings. A total of 175 lymph node were removed, median of 35 (range, 27–43) per patient in five patients who
had RC and ePLND while 12 (7%) harboured metastases. Sensitivity, specificity, accuracy and AUC for N-staging
were 0.20, 0.96, 0.80 and 0.58 on the ePLND template (10 regions) level.
Conclusions: 11C-acetate PET/MRI is feasible for staging of BC although sensitivity for the detection of nodal
metastases is low. Monitoring response to NAC shows promise and warrants evaluation in larger studies.
Trial registration: ClinicalTrials.gov Identifier: NCT01918592, registered August 8 2013
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Background
Approximately 77,000 new cases of bladder cancer (BC)
are diagnosed annually in USA [1]. In Europe, based on EU
science hub estimates, incidence of new BC cases was
131,000 in 2015, but there is large variability between
different countries [2]. Staging is based on TNM system
[3]. Ta tumors are treated with transurethral resection of
bladder tumor (TUR-BT). T1 and carcinoma in situ (Tis)
tumors have risk of progression and intravesical immuno-
therapy with Bacillus-Calmette-Guerin (BCG) instillations
is used to obtain local control and organ preservation [4].
Muscle invasive bladder cancer (MIBC) is an aggressive dis-
ease and standard treatment is radical cystectomy (RC), ac-
companied by pelvic lymph node dissection (PLND) [5]. In
addition to radical surgery, neoadjuvant chemotherapy
(NAC) has been demonstrated to increase overall survival
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in MIBC and is recommended by consensus guide-
lines [5, 6].
Staging of BC remains suboptimal with standard imaging
modalities such as computed tomography (CT) and ana-
tomical (T2- and T1-weighted imaging) magnetic reson-
ance imaging (MRI) [7, 8]. Compared to contrast enhanced
CT, MRI has better soft tissue contrast which may improve
local tumor evaluation [9]. Locoregional staging in particu-
lar is difficult, since normal-sized lymph nodes may
harbour metastases. The use of ultra-small paramagnetic
particles of iron oxide (USPIO) has shown some promise in
the detection of nodal metastases with MRI [10, 11] but still
remains an experimental approach with very limited
availability.
Positron emission tomography-CT (PET/CT) im-
aging has been widely investigated in BC in an at-
tempt to improve nodal staging but with limited
success [12–15]. PET/MRI is a novel combination of
two imaging modalities which could potentially offer
advantages for evaluation of MIBC over PET/CT.
Only a limited experience in staging of BC is available
with PET/MRI and specifically studies of tracers with
low excretion in urine are lacking [16]. Hence, we
undertook the current study to evaluate 11C-acetate
PET/MRI in initial staging and estimation of response
to NAC in patients with BC.
Methods
Patients
The study was approved by the ethical committee of
Hospital District of Southwest Finland and registered at
ClinicalTrials.gov (NCT01918592). Candidates for study
were screened in cystoscopy units in three participating
university hospitals. Eligible patients signed written
consent after verbal and written information.
Imaging protocol
All patients were imaged with an Ingenuity TF PET/MRI
scanner (Philips Medical Systems, Cleveland, OH). Details
of the physical performance of the system have already
been reported [17]. Before imaging, each patient had a
Foley catheter inserted holding 10 ml glycine in balloon
and the bladder was consequently filled with 100 ml sterile
saline. The patients were placed supine on the scanner
table. After completed MR-based attenuation correction
(see below) the table was rotated for PET scan and a me-
dian dose of 713 (range, 654–796) MBq of 11C-acetate
was injected intravenously and PET acquisition (two
4-min table positions) covering the whole pelvis was im-
mediately started.
MR-based attenuation correction (MRAC) was per-
formed using the vendor-provided method. The ana-
tomical MR acquisition (atMR) for MRAC was
performed using Repetition Time/Echo Time (TR/TE)
4.0/2.3 ms and flip angle 10°. Subsequently, MRAC
algorithm converts the atMR images by segmentation
and classification to attenuation correction maps con-
taining air (0.0 cm− 1), lung (0.022 cm− 1) and soft tis-
sue (0.096 cm− 1). This MRAC map was then used in
PET image reconstruction. All quantitative corrections
were applied to this reconstruction taking into ac-
count detector dead time, radioactivity decay, random,
scatter and photon attenuation. PET images were re-
constructed in a 144 × 144 matrix with an isotropic
voxel size of 4 mm following a fully 3-D
maximum-likelihood ordered subsets expectation
maximum (LM-OSEM) algorithm with 3 iterations
and 33 subsets using TOF technology.
After the PET scan, bladder was emptied and radio-
active urine was safely disposed. Bladder was re-filled
with 100 ml sterile saline and MRI examination was
performed.
T2-weighted imaging was performed using
single-shot turbo spin echo sequence with TR/TE
3618/130, field of view (FOV) 300 × 300 mm2, acqui-
sition voxel size 1.25 × 1.25 × 3.00 mm3, reconstruc-
tion voxel size 0.69 × 0.69 × 3.00 mm3 in axial
(acquisition time 1:30 min), sagittal (acquisition time
1:30 min) and coronal (acquisition time 1:12 min)
planes. Diffusion weighted imaging (DWI) covering
whole pelvis was performed using a single shot
SE-EPI sequence, monopolar diffusion gradient
scheme, and the following parameters: TR/TE 3148/
45, FOV 300 × 300 cm2, acquisition voxel size 2.5 ×
2.5 × 4.0 mm3, reconstruction voxel size 1.25 × 1.25 ×
4.00 mm3, b value 0 and 800 s/mm2, diffusion gradi-
ent timing (Δ) 21.6 ms, diffusion gradient duration
(δ) 8.3 ms, diffusion time (Δ-δ/3) 18.8 ms, SENSE
[18] factor of 2, partial-Fourier acquisition 0.69,
SPAIR fat suppression acquisition time 1:47 min per
position (two positions in total). Additional
T2-weighted imaging in axial plane with the same
slice location as DWI covering whole pelvis was ob-
tained using TR/TE 3148/45, FOV 300 × 300 cm2, ac-
quisition voxel size acquisition voxel size 1.25 × 1.25 ×
4.00 mm3, reconstruction voxel size 0.69 × 0.69 ×
4.00 mm3, acquisition time 1:05 min per position
(two positions in total). Additional B0 and B1 map-
ping were performed. Multiple additional experimen-
tal DWI acquisitions, a spin locking method were
acquired but not analyzed in the current study [19].
Detailed importable PET/MRI protocol is provided in
the supporting material.
PET/MRI images were evaluated by two radiolo-
gists (IJ, JV) in conjunction with an experienced nu-
clear medicine physician (JK). Primary tumor size,
possible muscle invasion and metastatic spread was
evaluated [20]. Lymph nodes were evaluated on
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pre-determined 10 regions (suspicion of metastasis vs.
benign) as described in Fig. 1.
Treatment
A diagnostic TUR-BT followed imaging after a me-
dian of 11 (range 1–21) days (Fig. 2) in the primary
tumor evaluation of 15 patients. A complete resection
was performed in each case and imaging findings did
not affect the extent of the procedure. Further treat-
ment after TUR-BT was done according to standard
guidelines [5, 21]. In addition to 15 patients who
underwent PET/MRI before TUR-BT, three MIBC
Fig. 1 Examined lymph node areas in radical cystectomy
Fig. 2 Flow chart of the study protocol. The trial consisted of two phases: in phase 1 accuracy of 11C-acetate PET/MRI was evaluated on 15 treatment
naive patients before any intervention of primary tumor. In phase 2 treatment response to Neoadjuvant chemotherapy (NAC) was evaluated in 5
patients undergoing 11C-acetate PET/MRI after transurethral resection of bladder tumor (TUR-BT) and neoadjuvant chemotherapy. 2 patients
participated in both phases of the study. In total, 18 patients were enrolled
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patients were enrolled after TUR-BT for NAC treat-
ment response evaluation.
NAC treatment response was evaluated in five patients
(Table 1). Two patients in this study phase were part of
both phases. Five patients received either 3 or 4 cycles of
cisplatin-gemcitabine according to treating hospital pol-
icy. Second 11C-acetate PET/MRI imaging was per-
formed a median of 21 (range, 11–33) days after
completion of NAC. Finally, open RC and extended (E)
PLND were performed according to predetermined ten
fields described in Fig. 1. Delay from NAC completion
to RC was 36 days (range 28-47 days). The selected
EPLND template was based on commonly known
lymphatic spread pathways [22]. In addition to extent of
primary tumour, each predetermined PLND area was
separately analysed from the PET/MRI data sets. For the
histopathological examination, the RC specimen and the
ten PLND areas were sent separately and were analysed
by an experienced uropathologist (PT).
Statistics
The statistical analysis was performed using Matlab (ver-
sion r2013a, The MathWorks Inc., Natick, MA). Sensi-
tivity, specificity and accuracy of 11C-acetate PET/MRI
for BT staging in 15 patients who underwent PET/MRI
before TUR-BT was compared with TUR-BT histopath-
ology specimens as ground truth. The classification was
performed in binary class: benign + non-muscle invasive
(Ta/Tis/T1) vs muscle invasive (T2-T4). In five patients
presenting with MIBC who underwent RC and PLND,
regional classification (10 regions of interest, in total 50
regions) between benign vs malignant LNs was per-
formed. Additional patient level analysis was performed.
Receiver operating characteristic curve analysis was used
to evaluate ability of 11C-acetate PET/MRI for primary
staging and detection of lymph node metastases. Area
under the receiver operating characteristic curve (AUC)
values were calculated using the trapezoid rule.
Ninety-five percent confidence interval for AUC values
were calculated from 100,000 bootstrap samples. SUV
measurements were compared using Bonferroni multiple
comparison test [23].
Results
In total, 15 patients underwent the primary tumour
evaluation and five response evaluation with two pa-
tients participating in both groups giving a total of 18
participants. Patient characteristics are presented in
Table 1. Despite careful and hygienic catheterization
three patients (17%, 3/18) developed urinary tract infec-
tion after imaging. Two patients subsequently required
hospitalization while one patient received antimicrobial
treatment at home. In these three patients underlying
bacteriuria could not be ruled out since bacteriuria had
not been screened before or at the time of enrolment.
Primary staging
All primary tumors were urothelial cancer and demon-
strated positive uptake of 11C-acetate. The median
maximum standardized uptake value (SUVmax) was 2.9
(range, 1.3–4.7). There was no difference between
SUVmax of MIBC versus superficial (clinical stage
Tis-T1) BC.
The sensitivity, specificity, accuracy and AUC (95%
confidence interval) values of 11C-acetate PET/MRI for
the detection of MIBC (primary BT staging) were 1.00,
0.69 and 0.73, and 0.85 (0.55–1.00), respectively (Figs. 3
and 4). The individual differences for all 15 patients be-
tween 11C-acetate PET/MRI and TUR-BT are presented
in Table 2.
Therapy response evaluation
All five patients with MIBC underwent NAC and had
RC and EPLND. NAC was generally well tolerated and
all 5 patients received the planned amount of cycles but
dose adjustment of anticancer drugs was necessary for 2
patients before surgery. Comparison of 11C-acetate PET/
MRI and histopathological evaluation on patient level
are presented in Table 3. Compared to histopathology
11C-acetate PET/MRI correctly staged three patients
(Figs. 4 and 5), overstaged one (Fig. 6) and understaged
one patient. True negative findings in BT were reported
in two patients and true positive in one patient, respect-
ively. Details are presented in the Supporting Material.
Lymph node metastases detection
The median number of evaluated nodes per patient was
35 (range 27–43). Of a total 175 LNs removed, 12 (7%)
Table 1 Patients’ characteristics
Primary tumor NACa
No of patients in phase of study 15 5
Gender (Male/Female) 13/2 5
Age (years) 67 (55–79) 65 (57–69)
ASA-score 2 (1–3) 2
BMI (kg/m2) 27 (23–31) 26 (23–30)
Treatment modality
TUR-BT and surveillance 5 N/A
TUR-BT and BCG 7 N/A
TUR-BT, NAC, RC and EPLND 2 5
TUR-BT, BCG and RCb 1 N/A
Mean values and range are given, when feasible. ASA-score The American
Society of Anesthesiologists physical status grading system; BMI body mass
index, TUR-BT Transurethral resection of bladder tumor, BCG Bacillus-Calmette-
Guerin bladder instillations, RC radical cystectomy, EPLND extended pelvic
lymph node dissection, N/A not applicable
a2 patients participated in both phases of the study
bRC due to disease progression
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harboured metastases. On patient level, two of the five
patients had nodal metastatic disease (Table 4, Fig. 5).
All metastatic LNs were found around the iliac arteries
and none were identified outside the pelvis (Fig. 6). The
sensitivity, specificity and accuracy of 11C-acetate PET/
MRI for the detection of LN metastases on the predeter-
mined 10 nodal areas were 0.2, 0.96, 0.88, respectively,
and AUC (95% confidence interval) value was 0.58. The
corresponding values on patient level were 0.5, 0.67, 0.6,
and 0.58 respectively (Table 4).
Discussion
This prospective registered clinical trial is the first study
to demonstrate feasibility of 11C-acetate PET/MRI in BC
staging and its potential to assist in monitoring response
to NAC. Compared to CT, MRI as the anatomic
Fig. 3 Pre-transurethral resection 11C-acetate PET/MRI (a, b, c) in a 75-year old male patient (number 3 in primary imaging) showing a
heterogenous lobulated mass on the left side of mid-line without extension (white arrow) to perivesical fat on T2-weighted image (a) or
an area of increased diffusion signal restriction (white arrow) extending beyond the bladder wall (b - b value 800 s/mm2 trace diffusion
weighted image). The lesion had increased 11C-acetate uptake (c - PET fused with T2-weighted image, SUV is scaled from 0.0 to 3.2). The
imaging findings were suggestive of T1 stage. The transurethral resection of bladder tumor specimen revealed stage T1, thus the findings
of 11C-acetate PET/MRI correctly staged the tumor
Fig. 4 Comparison of local bladder cancer staging (T-stage) on pre-transurethral resection (a, b, c) and post-chemotherapy 11C-acetate
PET/MRI (d, e, f) in a 63-year-old male patient (number 12 in primary imaging). A heterogenous lobulated mass on the right side of
mid-line with extension (white arrow) to perivesical fat seen on T2-weighted image (a), an area of increased diffusion signal restriction (white arrow)
beyond the bladder wall (b - b value 800 s/mm2 trace diffusion weighted image), an associated right sided hydroureter, and increased 11C-acetate
uptake (c - PET fused with T2-weighted image, SUV is scaled from 0.0 to 3.5) suggestive of T3 stage. On post-chemotherapy 11C-acetate PET/MRI,
residual abnormal wall thickening (green arrow) on T2-weighted image (d) and diffusion signal restriction extending to perivesical fat (e - b value
800 s/mm2 trace diffusion weighted image) was presented suggestive of T3 stage. The final cystectomy specimen revealed stage T2, thus the findings
of 11C-acetate PET/MRI were considered as true positive for muscle invasion
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modality may be favoured since CT is poor for evalu-
ation of muscle invasion. Similar to prostate cancer [24],
11C- acetate PET/MRI does not seem to offer a satisfac-
tory solution for the detection of metastatic LNs in pel-
vis due to limited accuracy.
11C-acetate PET/MRI demonstrated accuracy of 0.73
in primary tumor staging, detection of MIBC. In previ-
ous studies higher accuracy of MRI alone has been re-
ported [25]. Green et al. [25] noted, however, that
differentiation between T1 high grade tumor and T2
tumor is challenging even with known histopathology
and TUR-BT stage. Two studies of PET/MRI after
TUR-BT or with proven history of BC using
2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) report high
activity in urinary system and in inflammatory tissue
[26, 27]. This is clearly detrimental for evaluation of BT
because of suboptimal target-to-background ratio. In the
current trial, treatment naive patients with suspicion of
muscle invasion in cystoscopy were imaged minimizing
the impact of inflammatory reaction post TUR-BT.
11C-acetate did not miss any MIBC cases and we hy-
pothesise that 11C- acetate could outperform 18F-FDG
since accuracy of 18F-FDG is limited by urine extraction.
Although overstaging affected accuracy in the current
trial, it is less significant as clinical challenge than under-
staging, which is a common cause of treatment delay,
meaning execution of RC and ePLND.
Only three studies, all published in 2012, reported
evaluation of 11C-acetate PET/CT in bladder cancer.
Vargas et al. reported on 16 patients and compared
MRI, CT and 11C-acetate PET/CT before cystectomy
and PLND. They concluded that while all three modal-
ities had similar accuracy PET/CT carried a risk of
understaging [28]. Orevi et al. found in a study of 13 pa-
tients that 11C-acetate PET/CT was positive in 10 LNs,
of which five were malignant giving a specificity of 50%
[13]. Finally, Schröder et al. demonstrated that 11C-acet-
ate PET/CT showed specificity of 50% and sensitivity of
80% for the detection of LN metastases. They also noted
that intravesical instillation therapy with BCG yielded
falsely high positive findings in the resected tumor bed
of bladder wall as well as in LNs. [15]. Similar problems
were seen by Vargas et al. [28]. In comparison to all
these three PET/CT studies [13, 15, 28] in the current
trial, specificity of 50% on patient level for detection of
regional metastases was found. If one patient with hip
prostheses was discarded, sensitivity would have been
100%. It is tempting to assume that 11C-acetate PET/
MRI is comparable or better than PET/CT for primary
tumor evaluation. However, there are no studies directly
comparing PET/CT to PET/MRI in bladder cancer sta-
ging and, therefore, the issue remains a matter of further
research.
Our registered prospective trial is the third 11C -acet-
ate study evaluating LNs in BC. However, 11C -acetate
and PET-MRI have not been used as a surrogate modal-
ity before [13, 28, 29]. A pilot study demonstrating the
utility of 18F-FDG PET/MRI in BC staging has already
been conducted [26]. The results seem to favour PET/
MRI in LN evaluation compared to MRI alone, but the
number of study subjects was low and needs to be veri-
fied in larger studies. Orevi et al. demonstrated that
11C-choline and acetate were comparable in evaluation
of lymph node metastases [13], and recent meta-analytic
study [29] reports for both tracers low sensitivity and
Table 2 11C-acetate PET/MRI primary staging
Patient no PET-MRI TUR-BT pathology
1 T1 Tis
2 T1 Ta
3 T1 T1
4 T2 T1
5 T2 T1
6 T3 T2
7 T1 T1
8 T1 Ta
9 T1 Ta
10 T1 Ta
11 T1 T1
12 T3 T2
13 T3 T1
14 T2 Ta
15 T1 T1
PET/MRI positron emission tomography – magnetic resonance imaging, TUR-BT
transurethral resection of bladder tumor. T-stage according to the
TNM classification
Table 3 Treatment response evaluation to neoadjuvant
chemotherapy using 11C-acetate PET/MRI. Patients 1 and 2
participated in both phases of the trial, underwent PET/MRI
before any intervention and secondary PET/MRI was performed
after completion of NAC. Patients 3–5 were enrolled after TUR-
BT and underwent PET/MRI after completion of NAC. Imaging
after NAC prior RC was compared to RC pathology
Patient PET/MRI RC
Primary tumour LNM +/− Primary tumour LN n tot / n+
1 T0 + T0 27 / 0
2 T4 + T2 42 / 3
3a T0 – T3 27 / 9
4 T0 – T0 43 / 0
5 T3 – T2 36 / 0
175 / 12
PET/MRI positron emission tomography – magnetic resonance imaging, RC
radical cystectomy, LNM lymph node metastasis (+) = suspicion of presence;
(−) = suspicion of absence
aPatient had bilateral hip prostheses which distorted the image quality
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Fig. 5 Comparison of lymph node staging (N-stage) on pre-transurethral resection (a, b, c) and post-chemotherapy 11C-acetate PET/MRI (d, e, f)
in patient number 12, the same patient as in Fig. 4. 17 mm right obturator lymph node (a - white arrow on T2-weighted image) demonstrated
increased diffusion signal restriction (b - b value 800 s/mm2 trace diffusion weighted image) and increased 11C-acetate uptake (c - PET fused with
T2-weighted image, SUV is scaled from 0.0 to 3.5) suggestive of lymph node metastasis. On post-chemotherapy 11C-acetate PET/MRI, lymph node
decreased in size and measured 4 mm (d - green arrow on T2-weighted image) with increased diffusion signal (e - b value 800 s/mm2 trace
diffusion weighted image) and increased 11C-acetate uptake (f - PET fused with T2-weighted image, SUV is scaled from 0.0 to 3.0). SUVmax values
of the lymph node on the pre-transurethral resection (c) and post-chemotherapy 11C-acetate PET/MRI (f) were 3.4 and 2.8, respectively. The
lymph node was confirmed to be lymph node metastasis measuring 3 mm on extended pelvic lymph node dissection, thus the findings of 11
C-acetate PET/MRI were considered as true positive
Fig. 6 Comparison of lymph node staging (N-stage) on pre-transurethral resection (a, b, c) and post-chemotherapy 11C-acetate PET/MRI (d, e, f)
in a 66-year-old male (patient number 6 in primary imaging). 8 mm retroaortic lymph node (d - white arrow on T2-weighted image) demonstrated
increased diffusion signal restriction (b - b value 800 s/mm2 trace diffusion weighted image), and increased 11C-acetate uptake (c - PET fused with
T2-weighted image, SUV is scaled from 0.0 to 2.8) suggestive of lymph node metastasis. On post-chemotherapy 11C-acetate PET/MRI, lymph did not
decrease in size and measured 7 mm (d - green arrow on T2-weighted image) with increased diffusion signal (e - b value 800 s/mm2 trace diffusion
weighted image) and increased 11C-acetate uptake (f - PET fused with T2-weighted image, SUV is scaled from 0.0 to 2.8). SUVmax values of the lymph
node on the pre-transurethral resection (c) and post-chemotherapy 11C-acetate PET/MRI (f) was 1.7, 1.3, respectively. No lymph node metastases were
found on extended pelvic lymph node dissection, thus the findings of 11C-acetate PET/MRI were considered as false positive
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moderate specificity while heterogeneity of publications
limits further conclusions. Our sensitivity of 20% in LN
staging is in line with the meta-analysis and we could
conclude that the optimal tracer for evaluating urinary
tract and pelvic LNs remains to be found.
Studies comparing PET/CT vs. PET/MRI for the de-
tection of lymph nodes are lacking. 18F-FDG PET is
widely available and has been studied in multiple studies
enrolling BC patients, but prior studies were mainly per-
formed with PET/CT and some compared to CT alone
[30–32]. Overall, the results are conflicting. Swinnen et
al. found no benefit from adding PET to CT alone [30].
18F-FDG is highly active in urinary system and forced
urinary protocols and delayed execution of PET imaging
have been shown to improve performance of 18F-FDG
PET/CT [33]. Using these methods, excessive hydration
and use of diuretics can also be considered an extra bur-
den for the patient. Although the published evidence
does not support routine use of PET-imaging for BC sta-
ging, our results indicate that 11C-acetate is a viable
tracer option in BC staging.
Our study has several limitations. First, the number of
patients especially evaluated for NAC response was low.
Furthermore, patient no. 3 in NAC treatment response
group had bilateral hip prostheses, which caused B0 field
distortions and the image quality was not optimal. We
hypothesize that the patient’s largest metastatic 2.0 cm
LN would not have been missed if B0 field distortions
were fully compensated. Although excellent therapy re-
sponses were found (Figs. 4 and 5) the low number of
patients precludes definite conclusion about the value of
11C -acetate PET/MRI in setting of therapy response
evaluation. In contrast, compared to previous studies a
higher number of treatment (n = 15) naive patients
underwent baseline imaging, and allowed us to evaluate
performance of 11C -acetate PET/MRI without contribu-
tion of inflammation to findings. To decrease heterogen-
eity in future studies, BCG or chemotherapy ideally
should not be given before initial PET-MRI or PET-CT.
In the current trial T1-weighted imaging and dynamic
contract enhanced MRI were not performed. Before con-
ducting this trial, we have performed very careful
optimization of MRI acquisition protocol, done multiple
iterations of the acquisition protocol, and carefully opti-
mized the acquisition protocol with special attention on
DWI. As can be seen in Figs. 3, 4, 5 and 6, DWI was the
“workhorse “for TNM staging of BC. In order to
increase openness of our trial, promote #opensource re-
search (#OpenSourceTrial), we share our optimized MRI
acquisition protocol in supporting material.
Conclusion
In conclusion, we found a moderate accuracy for staging
of primary BC using 11C-acetate PET/MRI in this pilot
prospective registered clinical trial. In contrast, only a
limited sensitivity for detection of metastatic lymph
nodes and response to neoadjuvant chemotherapy was
found. Our findings do not advocate for routine use of
11C-acetate PET/MRI in staging of BC but consideration
of its potential role in future organ preservation trials
with combined use of imaging and other markers, such
as molecular information, is warranted.
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Table 4 11C-acetate PET/MRI lymph node evaluation
Area of interest Sensitivity Specificity Accuracy AUC
LN areas (n = 50) 0.20 0.96 0.88 0.58
On patient levela (n = 5) 0.50 0.67 0.60 0.58
aevaluation of LN positivity. Only 2 patients had LN metastases and the other
had hip prostheses
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